The Fund seeks to deliver attractive returns through exposure to equities of companies within the healthcare sector, with an emphasis on those involved in the development of new therapeutics, including biotechnology firms. It pursues this objective by investing in an equity long-short hedge fund, the SilverArc Capital Alpha Fund.
The strategy employs a low-net long/short equity approach focused on biotechnology, investing in equities and equity derivatives based on deep fundamental research. A specialized team of nine professionals combines scientific expertise with an extensive network of clinicians, researchers, and industry executives to support idea generation, underwriting, and disciplined risk management.
We believe biotechnology represents one of the most compelling opportunity sets in global equities, driven by accelerating drug innovation, expanding clinical pipelines, and sustained capital allocation toward life sciences. This environment creates opportunities to capture asymmetric upside from breakthrough developments while actively managing downside risk through a disciplined long/short investment framework.
Usamos dados pessoais e cookies para analisar o uso de nosso site, direcionar conteúdos e anúncios personalizados e aprimorar a sua experiência. Ao continuar navegando, você concorda com a nossa política de privacidade e política de cookies.
To change your current location please
select from ASA´s locations below.